Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease, is present in nine to 18 million people in America alone and up to a billion worldwide. Yet 39 years after its formal description, no single drug has yet been approved for its treatment. To discuss why therapies are proving so elusive, and where efforts will be made in the future, Front Line Genomics has gathered some of the most influential names in the field to discuss the problem in our latest webinar: New Approaches to the Old Hunt for NASH Therapies, held at 4pm BST on 11 July 2019.

NASH is caused by fatty build-ups in the liver which cause inflammation and damage the liver cells, potentially leading to scarring of the liver and cirrhosis. So far it is unknown why some people with fatty livers get NASH and others do not. No single test can diagnose NASH, though a combination of biopsies, medical history and a physical exam are common for determining whether an individual has the disease.

Similarly elusive are successful therapies to treat the disease: a number of big NASH trials have crashed out in the last few years, the most recent being a Novartis-partnered phase 2b trial from Conatus Pharmaceuticals that forced the company to lay off 40% of its staff.

It’s now a vital time to talk about new approaches to finding NASH therapies. Front Line Genomics has gathered some of the biggest names in NASH to discuss the problem, looking at topics including:

• Why are therapies for NASH proving so elusive?

• The drivers of NASH (pathophysiological and others)

• Is there anything out there that looks promising? What are these innovations doing differently?

• The promise of cell therapy and regenerative medicine

• What other, more NASH-specific, approaches should the field take in drug discovery and validation?

The webinar will be moderated by Dr Donna Cryer, President and CEO of the Global Liver Institute. Our speakers are:

• Robert Lumsden, PhD, Clinical Programme Manager, Genomics Medicine Ireland

• Sean Muthian, PhD, BS, MBA, Executive Director, External Science Innovations, Allergan

• James Trevaskis, PhD, Director, Cell Biology – Fibrosis/NASH Group, Gilead Sciences

• Jeffrey Gulcher, MD, PhD, Chief Scientific Officer & Co-founder, WuXi NextCODE

• Matthews O. Bradley, PhD, Chairman, President, & Founder, SAJE Pharma LLC

You can sign up for the webinar here.